Market Research Report
Global Nanotechnology in Drug Delivery Market
PublishedSeptember 2026
UpdatedSeptember 2026
IndustryHealthcare
PDF
Historical Range2020-2024
Regions Covered
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
$107.3B
2025 Market Size
$214.48B
2033 Forecast
10.4%
CAGR
200
Report Pages
Market Overview
The Global Nanotechnology in Drug Delivery Market is witnessing steady growth as the pharmaceutical and healthcare industries increasingly seek advanced drug delivery solutions that can improve treatment efficacy, enhance drug bioavailability, and reduce adverse effects. Nanotechnology-based drug delivery systems offer functional advantages such as targeted drug delivery, controlled and sustained release, improved drug solubility, enhanced stability, and better absorption. Growing demand from oncology, cardiovascular, neurological, infectious disease, and other therapeutic areas is creating sustained opportunities for these advanced drug delivery technologies. The increasing need to deliver medicines more precisely to specific tissues and cells while minimizing exposure to healthy tissues is further supporting market growth. In addition, advancements in nanoparticles, liposomes, polymeric nanoparticles, nanomicelles, dendrimers, and other nanotechnology platforms are helping manufacturers and researchers develop drug delivery systems with improved therapeutic performance. Growing investment in personalized medicine, targeted therapies, and nanomedicine research is also encouraging the development of innovative delivery solutions. The focus on improving treatment outcomes, reducing drug toxicity, enhancing patient compliance, and enabling controlled drug release is expected to further drive the adoption of nanotechnology-based drug delivery systems across various therapeutic applications.
Market Scope
|
Global Nanotechnology in Drug Delivery Market |
|||
|
Years Considered |
|||
|
Historical Period |
2020 - 2024 |
Market Size (2025) |
USD 107.3 Billion |
|
Base Year |
2025 |
Market Size (2033) |
USD 214.48 Billion |
|
Forecast Period |
2026 - 2033 |
CAGR (2026 – 2033) |
10.4% |
|
Segments Covered |
|||
|
By Nanotechnology Platform |
· Lipid Nanoparticles and Liposomes · Polymeric Nanoparticles · Nanocrystals · Polymeric Micelles · Dendrimers · Inorganic Nanoparticles · Other Advanced Nanocarriers |
||
|
By Route of Administration |
· Intravenous · Oral · Inhalation · Transdermal and Topical · Ocular · Other Specialized Delivery Routes |
||
|
By Therapeutic Application |
· Oncology · Gene Therapy and mRNA Delivery · Infectious Diseases and Vaccines · Neurological Disorders · Cardiovascular Diseases · Inflammatory and Autoimmune Disorders · Ophthalmology · Metabolic and Endocrine Disorders · Other Therapeutic Applications |
||
|
By End User |
· Pharmaceutical and Biotechnology Companies · Contract Development and Manufacturing Organizations · Hospitals and Specialty Clinics · Academic and Research Institutes |
||
|
Countries Catered |
|||
|
North America |
· United States · Canada · Mexico |
||
|
Europe |
· United Kingdom · Germany · France · Spain · Italy · Rest of Europe |
||
|
Asia Pacific |
· China · India · Japan · Australia · South Korea · Rest of Asia Pacific |
||
|
Latin America |
· Brazil · Argentina · Rest of Latin America |
||
|
Middle East & Africa |
· Saudi Arabia · South Africa · Rest of MEA |
||
|
Key Companies |
|||
|
· Pfizer Inc. · Novartis AG · Bristol Myers Squibb · Gilead Sciences, Inc. · Moderna, Inc. · Alnylam Pharmaceuticals, Inc. · BioNTech SE · AstraZeneca plc · Sanofi S.A. · Johnson & Johnson · Evonik Industries AG · Lonza Group · CordenPharma · Acuitas Therapeutics · Arcturus Therapeutics · Pacira BioSciences · Camurus AB · Nanobiotix S.A. · Nanoform Finland Plc · Precision NanoSystems |
|||
Market Dynamics
DRIVERS
Impact
Level
Level
- Demand for targeted therapy and precision medicine High impact
- Expanding pipeline of nano-enabled biologics and gene therapies High impact
RESTRAINTS
Impact
Level
Level
- Regulatory complexity and absent standardized evaluation frameworks Medium impact
OPPORTUNITIES
Impact
Level
Level
- Expansion into oncology and central nervous system disorders High impact
- Integration with personalized medicine and digital health Medium impact
CHALLENGES
Impact
Level
Level
- Long-term safety data gaps and manufacturing scalability Medium impact
Source: Secondary Research, Interviews with Experts, Foreclaro Analysis
Drivers
Conventional drug delivery often causes systemic toxicity and poor bioavailability. Nanoscale carriers enable precise targeting of diseased tissues while enhancing solubility and stability of therapeutic payloads. This approach improves treatment outcomes for cancer and neurological disorders while reducing side effects, driving rapid adoption across healthcare systems seeking more efficient and personalized treatment options. The success of lipid nanoparticle-based mRNA vaccines validated the commercial and regulatory feasibility of nanotechnology delivery platforms. This has triggered a wave of investment and strategic partnerships aimed at next-generation gene therapies, with large pharmaceutical companies collaborating with academic labs to refine encapsulation chemistries. As more candidates advance through clinical trials, regulatory comfort increases and the funnel for nano-based therapeutics widens across oncology, rare diseases, and metabolic disorders.
Restraints
The absence of harmonized characterization, testing, and reporting frameworks for nanoparticle drug delivery creates a structural barrier at every stage from research to approval. Without agreed protocols for measuring particle size distribution, protein corona composition, and drug release under physiologically relevant conditions, results across studies cannot be meaningfully compared. Regulatory agencies struggle to classify nanomedicines, and the lack of standardized evaluation methods raises concerns about safety, efficacy, and long-term effects, extending approval timelines and increasing costs.
Opportunities
Oncology remains the dominant application area, as nanocarriers enable higher dose intensities and localized release of chemotherapeutics. Gene therapy and mRNA indications are advancing rapidly, while neurology programs are gaining momentum by harnessing nanocarriers to cross the blood-brain barrier. Cardiovascular applications targeting atherosclerotic plaques represent another promising frontier, with preclinical models demonstrating significant improvements in targeting accuracy. Nano-carrier technologies are increasingly designed for customization based on individual molecular profiles and specific biomarkers. This convergence of diagnostic and therapeutic delivery systems enables personalized treatment plans with precise control over dosage, target sites, and release mechanisms. As healthcare providers and insurers recognize the advantages, their willingness to finance these innovations further propels market growth.
Challenges
Nanoparticle systems containing non-biodegradable materials may persist in organs for extended periods after administration, yet preclinical toxicology studies conducted over shorter durations cannot capture the effects of prolonged organ accumulation. The emergence of anti-PEG immune responses in clinical populations illustrates that nanoparticle-specific immunological effects may only become apparent after extended clinical use. Simultaneously, maintaining particle size, drug loading, sterility, and batch-to-batch consistency during scale-up remains difficult, with specialized equipment and technical expertise increasing production costs.
Market Regional Analysis
The Global Nanotechnology in Drug Delivery Market is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Demand for nanotechnology-based drug delivery systems varies across regions depending on pharmaceutical and biotechnology development, healthcare infrastructure, research and development investment, regulatory frameworks, and adoption of advanced drug delivery technologies. While North America has a strong position because of its advanced pharmaceutical and biotechnology industries, significant investment in nanomedicine research, and well-established healthcare infrastructure, Europe is supported by increasing research activities, advanced healthcare systems, and growing development of targeted and personalized therapies. Asia-Pacific is emerging as an important and rapidly expanding market due to increasing pharmaceutical manufacturing, growing healthcare expenditure, rising research and development activities, and expanding biotechnology capabilities across countries such as China, Japan, India, and South Korea. Latin America is supported by improving healthcare infrastructure and increasing access to advanced therapies, while the Middle East & Africa market is developing with growing healthcare investments, modernization of medical facilities, and increasing adoption of advanced pharmaceutical technologies.
Market Key Players
· Pfizer Inc.
· Novartis AG
· Bristol Myers Squibb
· Gilead Sciences, Inc.
· Moderna, Inc.
· Alnylam Pharmaceuticals, Inc.
· BioNTech SE
· AstraZeneca plc
· Sanofi S.A.
· Johnson & Johnson
· Evonik Industries AG
· Lonza Group
· CordenPharma
· Acuitas Therapeutics
· Arcturus Therapeutics
· Pacira BioSciences
· Camurus AB
· Nanobiotix S.A.
· Nanoform Finland Plc
· Precision NanoSystems
Recent Developments
In July 2026, Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients. The proposed acquisition adds an NMTi payload platform and two ADC assets, with the technology designed to deliver cancer-killing payloads directly to tumor cells.
In August 2026, Moderna reported positive Phase 3 results for its individualized neoantigen therapy, highlighting the company's continued development of mRNA-based therapeutic technologies. mRNA delivery is directly relevant to the broader advanced drug-delivery landscape, although this release does not itself describe a new nanotechnology delivery platform.
Table of Contents
Chapter 1 — Introduction
1.1. Report Description
1.2. Key Market Segments
1.3. Regulatory Scenario
1.4. Executive Summary
Chapter 2 — Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.3. Secondary Analyst Tools and Models
Chapter 3 — Market Dynamics
3.1. Market driver analysis
3.1.1. Rising prevalence of cancer, cardiovascular diseases, neurological disorders, and other chronic conditions is increasing demand for more effective and targeted drug delivery solutions.
3.1.2. Growing need for targeted and controlled drug delivery is encouraging the adoption of nanotechnology-based systems that can improve drug bioavailability and reduce systemic side effects.
3.2. Market restraint analysis
3.2.1. High research, development, formulation, and manufacturing costs associated with nanotechnology-based drug delivery systems can limit adoption.
3.3. Market Opportunity
3.3.1. Growing demand for targeted cancer therapies is creating opportunities for nanoparticle-based systems capable of delivering therapeutic payloads directly to tumor tissues.
3.4. Market Challenges
3.4.1. Maintaining consistent particle size, drug loading, release characteristics, and product quality during large-scale manufacturing remains a key challenge.
Chapter 4 — Market Variables and Outlook
4.1. SWOT Analysis
4.1.1. Strengths
4.1.2. Weaknesses
4.1.3. Opportunities
4.1.4. Threats
4.2. PESTEL Analysis
4.2.1. Political Landscape
4.2.2. Economic Landscape
4.2.3. Social Landscape
4.2.4. Technological Landscape
4.2.5. Environmental Landscape
4.2.6. Legal Landscape
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of Substitute
4.3.4. Threat of New Entrant
4.3.5. Competitive Rivalry
4.4. Value Chain Analysis
Chapter 5 — Global Nanotechnology in Drug Delivery Market: Nanotechnolog...
5.1. Global Nanotechnology in Drug Delivery Market value share and forecast, (2020 to 2033)
5.2. Incremental Growth Analysis and Infographic Presentation
5.3. Lipid Nanoparticles and Liposomes
5.4. Polymeric Nanoparticles
5.5. Nanocrystals
5.6. Polymeric Micelles
5.7. Dendrimers
5.8. Inorganic Nanoparticles
5.9. Other Advanced Nanocarriers
Chapter 6 — Global Nanotechnology in Drug Delivery Market: Route of Admi...
6.1. Global Nanotechnology in Drug Delivery Market value share and forecast, (2020 to 2033)
6.2. Incremental Growth Analysis and Infographic Presentation
6.3. Intravenous
6.4. Oral
6.5. Inhalation
6.6. Transdermal and Topical
6.7. Ocular
6.8. Other Specialized Delivery Routes
Chapter 7 — Global Nanotechnology in Drug Delivery Market: Therapeutic A...
7.1. Global Nanotechnology in Drug Delivery Market value share and forecast, (2020 to 2033)
7.2. Incremental Growth Analysis and Infographic Presentation
7.3. Oncology
7.4. Gene Therapy and mRNA Delivery
7.5. Infectious Diseases and Vaccines
7.6. Neurological Disorders
7.7. Cardiovascular Diseases
7.8. Inflammatory and Autoimmune Disorders
7.9. Ophthalmology
7.10. Metabolic and Endocrine Disorders
7.11. Other Therapeutic Applications
Chapter 8 — Global Nanotechnology in Drug Delivery Market: End User Esti...
8.1. Global Nanotechnology in Drug Delivery Market value share and forecast, (2020 to 2033)
8.2. Incremental Growth Analysis and Infographic Presentation
8.3. Pharmaceutical and Biotechnology Companies
8.4. Contract Development and Manufacturing Organizations
8.5. Hospitals and Specialty Clinics
8.6. Academic and Research Institutes
Chapter 9 — Global Nanotechnology in Drug Delivery Market: Regional Esti...
9.1. Global Nanotechnology in Drug Delivery Market value share and forecast, (2020 to 2033)
9.2. Incremental Growth Analysis and Infographic Presentation
9.3. North America
9.4. Europe
9.5. Asia Pacific
9.6. Latin America
9.7. MEA
Chapter 10 — Global Nanotechnology in Drug Delivery Market: Country Estim...
10.1. Global Nanotechnology in Drug Delivery Market value share and forecast, (2020 to 2033)
10.2. Incremental Growth Analysis and Infographic Presentation
10.3. United States
10.4. Canada
10.5. Mexico
10.6. United Kingdom
10.7. France
10.8. Germany
10.9. Italy
10.10. Spain
10.11. China
10.12. India
10.13. Japan
10.14. South Korea
10.15. Australia
10.16. Brazil
10.17. Argentina
10.18. Saudi Arabia
10.19. South Africa
Chapter 11 — Competitive Landscape
11.1. Company Market Share Analysis
11.2. Vendor Landscape
11.3. Competition Dashboard
Chapter 12 — Company Profiles
12.1.1. Company Overview
12.1.2. Financial Details
12.1.3. Product Analysis
12.1.4. Recent Developments
12.2. Novartis AG
12.2.1. Company Overview
12.2.2. Financial Details
12.2.3. Product Analysis
12.2.4. Recent Developments
12.3. Bristol Myers Squibb
12.3.1. Company Overview
12.3.2. Financial Details
12.3.3. Product Analysis
12.3.4. Recent Developments
12.4. Gilead Sciences, Inc.
12.4.1. Company Overview
12.4.2. Financial Details
12.4.3. Product Analysis
12.4.4. Recent Developments
12.5. Moderna, Inc.
12.5.1. Company Overview
12.5.2. Financial Details
12.5.3. Product Analysis
12.5.4. Recent Developments
12.6. Alnylam Pharmaceuticals, Inc.
12.6.1. Company Overview
12.6.2. Financial Details
12.6.3. Product Analysis
12.6.4. Recent Developments
12.7. BioNTech SE
12.7.1. Company Overview
12.7.2. Financial Details
12.7.3. Product Analysis
12.7.4. Recent Developments
12.8. AstraZeneca plc
12.8.1. Company Overview
12.8.2. Financial Details
12.8.3. Product Analysis
12.8.4. Recent Developments
12.9. Sanofi S.A.
12.9.1. Company Overview
12.9.2. Financial Details
12.9.3. Product Analysis
12.9.4. Recent Developments
12.10. Johnson & Johnson
12.10.1. Company Overview
12.10.2. Financial Details
12.10.3. Product Analysis
12.10.4. Recent Developments
12.11. Evonik Industries AG
12.11.1. Company Overview
12.11.2. Financial Details
12.11.3. Product Analysis
12.11.4. Recent Developments
12.12. Lonza Group
12.12.1. Company Overview
12.12.2. Financial Details
12.12.3. Product Analysis
12.12.4. Recent Developments
12.13. CordenPharma
12.13.1. Company Overview
12.13.2. Financial Details
12.13.3. Product Analysis
12.13.4. Recent Developments
12.14. Acuitas Therapeutics
12.14.1. Company Overview
12.14.2. Financial Details
12.14.3. Product Analysis
12.14.4. Recent Developments
12.15. Arcturus Therapeutics
12.15.1. Company Overview
12.15.2. Financial Details
12.15.3. Product Analysis
12.15.4. Recent Developments
12.16. Pacira BioSciences
12.16.1. Company Overview
12.16.2. Financial Details
12.16.3. Product Analysis
12.16.4. Recent Developments
12.17. Camurus AB
12.17.1. Company Overview
12.17.2. Financial Details
12.17.3. Product Analysis
12.17.4. Recent Developments
12.18. Nanobiotix S.A.
12.18.1. Company Overview
12.18.2. Financial Details
12.18.3. Product Analysis
12.18.4. Recent Developments
12.19. Nanoform Finland Plc
12.19.1. Company Overview
12.19.2. Financial Details
12.19.3. Product Analysis
12.19.4. Recent Developments
12.20. Precision NanoSystems
12.20.1. Company Overview
12.20.2. Financial Details
12.20.3. Product Analysis
12.20.4. Recent Developments
Market Segment Analysis
The Global Nanotechnology in Drug Delivery Market is segmented by function, technology, formulation, and end-use industry.
By Nanotechnology Platform, the market includes lipid nanoparticles and liposomes, polymeric nanoparticles, nanocrystals, polymeric micelles, dendrimers, inorganic nanoparticles, and other advanced nanocarriers. Lipid nanoparticles and liposomes account for a significant share of demand due to their ability to encapsulate and protect therapeutic molecules while supporting targeted and controlled drug delivery. Polymeric nanoparticles are gaining interest because they offer controlled drug release, improved drug stability, and opportunities for targeted delivery. Nanocrystals are increasingly used to improve the solubility and bioavailability of poorly water-soluble drugs, while polymeric micelles are being explored for the delivery of hydrophobic and complex therapeutic compounds. Dendrimers and inorganic nanoparticles are finding applications in targeted therapies, imaging, and advanced drug delivery, while other advanced nanocarriers are being developed for emerging applications including biologics, nucleic acids, and personalized therapies.
By Route of Administration, the market includes intravenous, oral, inhalation, transdermal and topical, ocular, and other specialized delivery routes. Intravenous administration represents an important segment as it enables direct delivery of nanotechnology-based formulations into the bloodstream and is widely used in oncology and other systemic treatments. Oral delivery is gaining attention because nanotechnology can improve the solubility, stability, absorption, and bioavailability of drugs administered through the gastrointestinal tract. Inhalation-based delivery is being explored for pulmonary diseases and localized drug delivery to the lungs, while transdermal and topical delivery systems offer opportunities for controlled and localized treatment. Ocular delivery is increasingly being developed to improve drug retention and penetration in eye tissues, while other specialized delivery routes are being investigated for applications requiring precise and targeted drug administration.
By Therapeutic Application, the market includes oncology, gene therapy and mRNA delivery, infectious diseases and vaccines, neurological disorders, cardiovascular diseases, inflammatory and autoimmune disorders, ophthalmology, metabolic and endocrine disorders, and other therapeutic applications. Oncology accounts for a significant share of demand as nanotechnology-based systems can support targeted drug delivery, controlled release, and improved distribution of anticancer therapies. Gene therapy and mRNA delivery are gaining significant interest as lipid nanoparticles and other advanced nanocarriers can facilitate the delivery of nucleic acid-based therapeutics. Infectious diseases and vaccines are also benefiting from nanotechnology platforms designed to improve antigen delivery and therapeutic performance. Meanwhile, neurological, cardiovascular, inflammatory, ophthalmic, metabolic, and endocrine applications are being explored to overcome biological barriers and improve the delivery of therapeutic molecules to specific tissues.
By End User, the market includes pharmaceutical and biotechnology companies, contract development and manufacturing organizations, hospitals and specialty clinics, and academic and research institutes. Pharmaceutical and biotechnology companies represent a major end-user segment due to their extensive investment in drug development, nanomedicine research, and commercialization of advanced therapeutic products. Contract development and manufacturing organizations are gaining importance as pharmaceutical companies increasingly utilize specialized external capabilities for formulation development, process optimization, and manufacturing of complex nanotechnology-based drug delivery systems. Hospitals and specialty clinics are involved in the application and administration of approved nanotechnology-enabled therapies, particularly in specialized treatment areas such as oncology. Academic and research institutes continue to contribute to the development of new nanocarriers, drug delivery mechanisms, and emerging therapeutic applications through fundamental and translational research.
Segmentation
- Nanotechnology Platform
- Route of Administration
- Therapeutic Application
- End User
- Regional
Published by
Foreclaro Global Research
Want the complete segment breakdown?
Download Sample
Nanotechnology Platform
Lipid Nanoparticles and Liposomes
Polymeric Nanoparticles
Nanocrystals
Polymeric Micelles
Dendrimers
Inorganic Nanoparticles
Other Advanced Nanocarriers
Route of Administration
Intravenous
Oral
Inhalation
Transdermal and Topical
Ocular
Other Specialized Delivery Routes
Therapeutic Application
Oncology
Gene Therapy and mRNA Delivery
Infectious Diseases and Vaccines
Neurological Disorders
Cardiovascular Diseases
Inflammatory and Autoimmune Disorders
Ophthalmology
Metabolic and Endocrine Disorders
Other Therapeutic Applications
End User
Regional
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Methodology
Review our research methodology and quality standards for details about source selection, validation, forecasting, and review.
Primary interviews may be conducted during report customization or final validation, depending on the agreed study scope.
At Foreclaro Global Research, our research methodology is built to deliver clear, data-backed intelligence that supports confident decision-making. By combining rigorous secondary research, primary validations, and advanced forecasting models, we produce insights that are not only reliable but also strategically relevant for our clients.
1. Defining the Research Framework
Every study begins with a clear understanding of our client’s goals. We establish the market scope, define critical variables, and build a research framework tailored to the specific project. This upfront clarity ensures that our findings are sharply aligned with the strategic questions being addressed.
2. Robust Data Collection
Our analysts extract high-integrity data from a broad mix of credible sources including government databases, annual reports, regulatory filings, trade publications, scientific journals, and trusted industry portals. This secondary research is then supported with targeted primary inputs through interviews with key industry stakeholders—such as executives, subject matter experts, and channel partners—to capture real-world insights and contextual depth.
3. Advanced Forecasting and Modeling
To estimate market size and growth, we employ a hybrid of top-down and bottom-up modeling techniques. Our analysts apply proven forecasting models using historical data trends, economic indicators, technology adoption rates, and demand patterns. Sensitivity analysis and scenario modeling (base, optimistic, conservative) are incorporated to account for market volatility and uncertainty.
4. Data Triangulation and Validation
Accuracy is non-negotiable. We cross-validate every data point by triangulating it across three dimensions: source credibility, numerical consistency, and contextual alignment. This ensures our insights are not just statistically correct but strategically dependable. Discrepancies are resolved using subject expertise and multi-perspective reviews to deliver a balanced, unbiased analysis.
5. Quality Assurance and Final Review
Before delivery, each report undergoes a stringent quality assurance process. Our research output is reviewed for structure, clarity, consistency, and compliance with global standards. The final deliverable is tailored for decision-makers, whether it's a comprehensive industry report, data dashboard, or strategic presentation.
Why Our Methodology Works
What sets us apart is our adaptive data architecture and our commitment to analytical clarity. Every study is built with flexibility to accommodate dynamic markets, while our team blends quantitative rigor with domain-specific expertise. This allows us to deliver research that goes beyond information, we deliver intelligence that leads to action.
Support Questions
What is the current market size of the Global Nanotechnology in Drug Delivery Market?
The current market size of the Global Nanotechnology in Drug Delivery Market is estimated to be USD 107.3 billion.
What is the expected growth rate (CAGR) for the nanotechnology in drug delivery market from 2026 to 2033?
Which nanotechnology platforms are covered in the report?
What are the main therapeutic applications of nanotechnology in drug delivery?
How is the Global Nanotechnology in Drug Delivery Market segmented by route of administration?
What are the main drivers of the Nanotechnology in Drug Delivery Market?
Who are the key players in the Global Nanotechnology in Drug Delivery Market?
What challenges does the nanotechnology in drug delivery market face?
Which regions are analyzed in the Global Nanotechnology in Drug Delivery Market report?
What market opportunities exist within nanotechnology for drug delivery?
What is the forecast market size for nanotechnology in drug delivery by 2033?
What methodologies are used in the research for this market report?
What are the different end users for nanotechnology in drug delivery?
How does nanotechnology improve drug delivery systems?